Drug intelligence / Profile preview

Zesteem

Development stage: Phase 2
Lead developer: Renovo
Modality: Small Molecules
Administration: Intradermal

Overview

Zesteem is an intradermal formulation of 17β-Estradiol, a naturally occurring steroid hormone. Developed by Renovo, it is being investigated for its efficacy in accelerating early wound healing of punch biopsy skin wounds in both male subjects and post-menopausal female subjects. The drug is administered once before the biopsy at various doses.

Brand names: Zesteem
Other names: 17β-estradiolestradiol

Targets

ER (Estrogen receptor)

Beyond the preview

Go deeper on Zesteem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zesteem.

Explore the full profile